Clarity Pharmaceuticals has received the Fast Track designation by the US FDA for its 64Cu-SAR-bisPSMA candidate for PET imaging in diagnosing prostate cancer. This drug is planned to detect metastasis in patients who are potential candidates for initial definitive therapy.
The drug is currently being tested in its registrational Phase III trial, CLARIFY, and Phase I/II trial, COBRA, for two different indications relating to prostate cancer treatment. In previous studies, the drug is claimed to be safe and effective in detecting prostate cancer in patients. It also reportedly has a longer half-life and can identify smaller lesions compared to gallium-68 and fluorine-18-based diagnostics.
Clarity Pharmaceuticals is a clinical-stage radiopharmaceutical company focused on developing next-generation oncology treatments. It leverages its proprietary Targeted Copper Theranostic (TCT) platform, which uses copper isotopes for diagnostic imaging and therapy. Clarity's lead product, SAR-bisPSMA, is being developed for prostate cancer diagnosis and treatment. Its product pipeline also includes SAR-Bombesin and SARTATE for various cancer indications.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.